A Novel Compound NSC745885 Exerts an Anti-Tumor Effect on Tongue Cancer SAS Cells In Vitro and In Vivo
Figure 9
Comparisons of the safety and the anti-tumor efficiency between NSC745885 and doxorubicin.
The cancer cell implanted NOD/SCID mice were administered with NSC745885 (NSC, 2 mg/kg/d) or doxorubicin (Dox, 2 mg/kg/d) on day 3. (A) The survival rates between NSC745885 and doxorubicin treated mice were assessed. There are no experimental mice were dead under NSC745885 treatment by day 11. By contrast, 50% of doxorubicin treated mice were dead (n = 10). (B) The body weights of doxorubicin treated mice were significant decreased when compared to NSC745885-treated group from day 3 to day 11 after the beginning of drug treatment. (C) SAS cells were inoculated into NOD/SCID mcie, and the treatments of doxorubicin or NSC745885 were started at day 3 after cell inoculation. Engrafted tumors were isolated on day 11 after SAS cell inoculation (n = 9). (D) There are no significant differences between NSC745885-treated and doxorubicin-treated groups (n = 9).